鼻咽癌患者中CD4~+CD25~+T细胞与CCR4的相关性

目的 探讨鼻咽癌患者全身及肿瘤局部的免疫状态及其与CC类趋化因子受体-4(CCR4)的关系.方法 采用流式细胞术检测初诊鼻咽癌患者组织(25例)及外周血(35例)中CD4~+CD25~+T细胞与CCR4阳性细胞在淋巴细胞中的比例,并进行统计学分析.结果 鼻咽癌组织及外周血中CD4~+CD25~+T细胞及CCR4阳性细胞的比例高于对照组(P<0.05);两种细胞在鼻咽癌组织中的比例高于外周血(P<0.05),而对照组外周血与组织中却无明显差别(P>0.05);鼻咽癌Ⅲ+Ⅳ期组织中的 CD4~+CD25~+T细胞比例高于Ⅰ+Ⅱ期(P<0.05),外周血中两组无明显差别(P>0.05);鼻咽癌组织及外周血中的CD4~+CD25~+T细胞与CCR4阳性细胞存在正相关关系.结论 鼻咽癌患者存在不同程度的免疫抑制,肿瘤局部免疫抑制更为严重;CD4~+CD25~+T细胞的比例与鼻咽癌分期相关,分期越晚,该细胞比例越高;CCR4在介导CD4~+CD25~+T 细胞趋化到肿瘤局部的过程中起了一定作用.

Correlation between CD4~+CD25~+T cells and CCR4 in human nasopharyngeal carcinoma

Objective To explore the immune function of the whole body and the tumor site of human nasopharyngeal carcinoma (NPC) patients as well as its correlation with CCR4. Methods The ratios of CD4~+CD25~+T cells and CCR4+cells to lymphocytes were measured by flow cytometry in tissues (25 cases) and peripheral blood (35 cases) from nasopharyngeal carcinoma patients, and then statistical analysis was made. Results The ratios of CD4~+CD25~+T cells and CCR4+ cells in tissue and peripheral blood of NPC were higher than those in the control group (P<0.05). In NPC the ratios of the two cells in tissue were higher than in peripheral blood respectively (P<0.05), but there was no such difference between tissue and peripheral blood in the control group (P>0.05). The ratio of CD4~+CD25~+T cells in tissue at stage Ⅲ+Ⅳ was higher than that at stage Ⅰ+Ⅱ of NPC (P<0.05), but there was no such difference between the two stages in peripheral blood in NPC. There was a positive correlation between CD4~+CD25~+T cells and CCR4+ cells in tissue and peripheral blood of NPC (P<0.05). Conclusion NPC patients have different immunosuppression, and there is even more severe immunosuppression in the tumor site. The ratio of CD4~+CD25~+T cells is correlated with the stage of NPC. Therefore, as NPC progresses to later stages, the percentage of CD4~+CD25~+T cells is increased, which is correlated with poor prognosis. CCR4 plays an important role in reactant of CD4~+CD25~+T cells to tumor sites, and is resistant to immunosurveillance.